Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Folotyn
Pralatrexate is an antifolate antineoplastic agent indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). It is a folate analog that inhibits dihydrofolate reductase (DHFR), a key enzyme in folate metabolism, leading to the disruption of DNA and RNA synthesis and ultimately cell death. Pralatrexate is specifically designed to have enhanced cellular uptake compared to other antifolates, particularly in tumor cells expressing the reduced folate carrier (RFC).
For the treatment of relapsed or refractory peripheral T-cell lymphoma.
Pralatrexate can cause severe or fatal toxicities, including myelosuppression (bone marrow suppression), mucositis (inflammation of the mucous membranes), renal (kidney) toxicity, and gastrointestinal toxicity. Patients should be carefully monitored for these toxicities during treatment.
Outcome:
Increased risk of myelosuppression
Mechanism:
Additive myelosuppressive effects
Outcome:
Decreased pralatrexate efficacy
Mechanism:
May interfere with pralatrexate's mechanism of action
Outcome:
Potential for minor increase in liver enzymes
Mechanism:
Both drugs are metabolized by the liver
Most likely new formulation: Liposomal or nanoparticle delivery system for improved efficacy and reduced toxicity (Year: 2026, 70% confidence)
Based on current clinical trial data and post-marketing surveillance, there is a low likelihood (<5%) of any major label changes or new black box warnings being issued within the next 2 years.
Antineoplastic Agent, Antifolate, DHFR Inhibitor
Folate Analog